Current and Emerging Direct Oral Anticoagulants: State-of-the-Art
- 19 June 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 45 (05) , 490-501
Abstract
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various stages, reducing clot development and ultimately lowering the risk of developing new-onset or recurrent thrombosis. Although the long history of anticoagulant drugs has been characteristically shaped by coumarin and heparin derivatives, a new generation of direct oral anticoagulants (DOACs), which specifically inhibit thrombin or activated factor X, combine many advantages of their progenitor drugs, and hence are prepotently revolutionizing the landscape of antithrombotic therapy. Several drugs (apixaban [BMS-562247], dabigatran [BIBR953], edoxaban [DU-1766], rivaroxaban [BAY 59–7939]) have already received widespread approval by national or supranational medicinal agencies. This narrative article provides a state-of-the-art for these and for several other DOACs at different stages of clinical evaluation (betrixaban, darexaban, eribaxaban, letaxaban, nokxaban), and certain others whose development has been discontinued (AZD-0837, fidexaban, LY517717, odiparcil, otamixaban, TTP889, and ximelagatran). What clearly emerges from our analysis is that DOACs sharing very similar mechanisms of action are still characterized by different efficacy and safety profiles. This not only depends on biochemical, biological, and pharmacokinetic characteristics, but also on lack of standardization between different clinical trials in terms of targeted disease, patient recruitment, sample size, duration and endpoints, as well as lack of harmonization around procedures used for drug licensing. These factors contribute to challenging the minds of physicians, who may find difficulty navigating their way through multiple indications, different pharmacological profiles, various side effects, and specific drug-to-drug interactions. Such considerations also burden laboratory professionals, who may face organizational and economic challenges in developing and/or implementing multiple assays to assess the pharmacodynamics (effect on coagulation) or pharmacokinetics (drug levels) of DOACs.Keywords
This publication has 61 references indexed in Scilit:
- An adaptive‐design dose‐ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgeryJournal of Thrombosis and Haemostasis, 2013
- Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory MedicineClinical Chemistry and Laboratory Medicine (CCLM), 2012
- Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitorEuropean Journal of Pharmacology, 2011
- RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEuropean Heart Journal, 2011
- Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2)Journal of Thrombosis and Haemostasis, 2010
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgeryThrombosis and Haemostasis, 2010
- Development of idraparinux and idrabiotaparinux for anticoagulant therapyThrombosis and Haemostasis, 2009
- Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosisThrombosis and Haemostasis, 2008
- Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory studyJournal of Thrombosis and Haemostasis, 2007
- A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgeryJournal of Thrombosis and Haemostasis, 2007